FDA rejects schizophrenia drug from Teva
![Danish national Kåre Schultz is chief executive of Teva, which has just received the FDA's thumbs-down for its candidate drug against schizophrenia | Photo: Amir Cohen/Reuters/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13940745.ece/ALTERNATES/schema-16_9/20190219-104407-5-6720x3772ma.jpg)
A potentially new treatment for schizophrenia has been sent back to the development phase, the pharmaceutical firm behind the drug, Teva, has announced in a press release on Tuesday.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk sues Teva over generic drug development
For subscribers